Letrozole 2.5 mg

• Letrozole 2.5 mg
• Brand: Magnus Pharmaceuticals
• Content: 50 tablets | 2.5 mg per tablet
• Manufactured in: Europe

Product Overview

Letrozole 2.5 mg is a third-generation, non-steroidal aromatase inhibitor (AI) that irreversibly binds the CYP19 enzyme to suppress estrogen biosynthesis. Designed for advanced hormone modulation studies, it supports research into testosterone enhancement, post-cycle therapy (PCT), fertility pathways, and estrogen-receptor positive (ER+) tumor models.

A single 2.5 mg oral dose reduces serum estradiol (E) by 60–80% within 24 hours and maintains suppression for 48 hours, supported by a 42–48 hour mean half-life. In male models, letrozole increases LH, FSH, and endogenous testosterone while improving sperm count—without impacting adrenal androgens. Exposure is prohibited in all WADA-sanctioned settings.

Key Research Highlights

• Potent estrogen suppression: 80% reduction in serum estradiol (E) achieved within 24 h after 2.5 mg dosing [NCBI]
• Endogenous testosterone boost: Studies in male infertility show LH, FSH, T, and sperm quality after 8–16 weeks [ScienceDirect, PMC]
• Pharmacokinetics: Oral bioavailability ~100%, t 42–48 h, steady-state in 2–6 weeks [DrugBank, PMC]
• Common side effects: Hot-flushes, joint discomfort, fatigue, and menopausal-like symptoms [NHS, Breast Cancer Now]
• Long-term risks: Reductions in bone-mineral density and lipid imbalances documented in chronic protocols [PMC]

Suggested Laboratory Applications

Aromatase inhibition and estrogen suppression modeling

Testosterone recovery and hormonal modulation

Fertility enhancement trials in male hypogonadism

PCT protocols in anabolic research models

ER+ breast cancer resistance pathways (e.g. tamoxifen-resistant models)

Technical Specifications

Detection Window

2 days (varies by protocol)

Documented Benefits

estrogen 80%, LH/FSH, T, fertility support, anti-ER+ tumor adjunct

Main Risks

BMD, joint pain, lipid alterations, fatigue, menopausal symptoms

Total Active Compound

125 mg per carton (2.5 mg 50 tablets)

Shelf-life

36 months (manufacturer specification)

PubChem-Supported Research Insights

Irreversibly inhibits aromatase enzyme (CYP19)

Maintains 80% estradiol suppression for 48+ hours

Improves testosterone-to-estradiol ratio without adrenal disruption

Increases LH and FSH in male fertility research

Used as an adjunct in tamoxifen-resistant ER+ tumor protocols

Documented Research Side Effects

Hot flashes and joint discomfort common

Potential for bone-density loss with chronic use

Altered lipid profiles: LDL / HDL

Fatigue and hormonal mood shifts

High doping detectability under WADA S4 classification

Handling & Compliance

For Research Use Only — Not for human or veterinary useStore at 15–25°C, protect from light and moisturePurchase confirms qualified researcher statusListed on WADA Prohibited List S4 — any exposure may yield a positive doping result